JP2002532079A - 補体活性化に関連するレクチン補体経路を調節するための方法および産物 - Google Patents

補体活性化に関連するレクチン補体経路を調節するための方法および産物

Info

Publication number
JP2002532079A
JP2002532079A JP2000587802A JP2000587802A JP2002532079A JP 2002532079 A JP2002532079 A JP 2002532079A JP 2000587802 A JP2000587802 A JP 2000587802A JP 2000587802 A JP2000587802 A JP 2000587802A JP 2002532079 A JP2002532079 A JP 2002532079A
Authority
JP
Japan
Prior art keywords
mbl
isolated
peptide
composition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000587802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002532079A5 (https=
Inventor
グレゴリー エル． スタール，
チャールズ ディー． コラード，
Original Assignee
ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド filed Critical ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド
Publication of JP2002532079A publication Critical patent/JP2002532079A/ja
Publication of JP2002532079A5 publication Critical patent/JP2002532079A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000587802A 1998-12-15 1999-12-15 補体活性化に関連するレクチン補体経路を調節するための方法および産物 Pending JP2002532079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11239098P 1998-12-15 1998-12-15
US60/112,390 1998-12-15
PCT/US1999/029919 WO2000035483A1 (en) 1998-12-15 1999-12-15 Methods and products for regulating lectin complement pathway associated complement activation

Publications (2)

Publication Number Publication Date
JP2002532079A true JP2002532079A (ja) 2002-10-02
JP2002532079A5 JP2002532079A5 (https=) 2007-02-15

Family

ID=22343639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000587802A Pending JP2002532079A (ja) 1998-12-15 1999-12-15 補体活性化に関連するレクチン補体経路を調節するための方法および産物

Country Status (4)

Country Link
EP (1) EP1140171A4 (https=)
JP (1) JP2002532079A (https=)
CA (1) CA2347734A1 (https=)
WO (1) WO2000035483A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532968A (ja) * 2010-06-19 2013-08-22 メモリアル スローン−ケタリング キャンサー センター 抗ｇｄ２抗体
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2003507338A (ja) * 1999-08-13 2003-02-25 ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用
NZ523900A (en) * 2000-07-13 2004-02-27 Jens Christian Jensenius Isolation and characterisation of a mannan-binding lectin (MBL) associated serine protease (MASP-2) and uses thereof to treat infections
EP1186299A1 (en) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
AU2004216176B2 (en) * 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
EP1625166B1 (en) 2003-05-12 2015-04-08 Helion Biotech ApS Antibodies to masp-2
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8524453B2 (en) 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2704743B1 (en) 2011-05-04 2020-03-11 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
CN108588033B (zh) * 2018-04-24 2021-09-24 富恩生物技术（成都）有限公司 杂交瘤细胞株、cd31单克隆抗体、制备方法及应用
CN115120705B (zh) * 2022-07-07 2025-01-28 新乡医学院 甘露聚糖结合凝集素在抑制细胞衰老方面的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502758A (ja) * 1989-01-26 1992-05-21 シュタイゲルヴァルト　アルツネイミッテルヴェルク　ゲセルシャフト　ミット　ベシュレンクター　ハフトゥング 経口投与のためのｎ―アセチルグルコサミン製剤
JPH06121695A (ja) * 1992-10-13 1994-05-06 Fuji Yakuhin Kogyo Kk 抗ヒトマンノース結合蛋白モノクローナル抗体およびその利用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
FI900808A7 (fi) * 1987-08-20 1990-02-19 Childrens Medical Center Ihmisen mannoosia sitova proteiini
WO1991006010A1 (en) * 1989-10-11 1991-05-02 Institute Of Child Health Diagnostic procedure
WO1993018775A1 (en) * 1992-03-19 1993-09-30 The University Of British Columbia Method and composition for suppression of side effects of anti-inflammatory drugs
JPH07238100A (ja) * 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5998173A (en) * 1996-02-20 1999-12-07 The University Of Bristish Columbia Process for producing N-acetyl-D-glucosamine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502758A (ja) * 1989-01-26 1992-05-21 シュタイゲルヴァルト　アルツネイミッテルヴェルク　ゲセルシャフト　ミット　ベシュレンクター　ハフトゥング 経口投与のためのｎ―アセチルグルコサミン製剤
JPH06121695A (ja) * 1992-10-13 1994-05-06 Fuji Yakuhin Kogyo Kk 抗ヒトマンノース結合蛋白モノクローナル抗体およびその利用

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532968A (ja) * 2010-06-19 2013-08-22 メモリアル スローン−ケタリング キャンサー センター 抗ｇｄ２抗体
US9315585B2 (en) 2010-06-19 2016-04-19 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
US9688772B2 (en) 2010-06-19 2017-06-27 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
US10287365B2 (en) 2010-06-19 2019-05-14 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies

Also Published As

Publication number Publication date
CA2347734A1 (en) 2000-06-22
EP1140171A4 (en) 2002-03-13
WO2000035483A1 (en) 2000-06-22
EP1140171A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
JP2002532079A (ja) 補体活性化に関連するレクチン補体経路を調節するための方法および産物
US7273925B1 (en) Methods and products for regulating lectin complement pathway associated complement activation
EP2195024B1 (en) Method of inhibiting complement activation with factor bb specific antibodies
KR101439828B1 (ko) 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
DK2033659T3 (en) Komplementaktiveringsinhibitorer
DK2262831T3 (en) ANTI-Properdin ANTIBODIES
US7959919B2 (en) Method of inhibiting factor B-mediated complement activation
JP4660189B2 (ja) 抗血小板自己抗体およびそのインヒビターに関連する組成物、方法およびキット
JP6709212B2 (ja) Ｌｏｘ１特異的結合タンパク質及びその使用
JP2021527698A (ja) 様々な血栓性の疾患および障害の治療のためのｍａｓｐ−２を阻害する組成物および方法
JP2018510613A (ja) 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）抗体およびその派生使用
CN109988240A (zh) 抗gpc-3抗体及其用途
US20040091494A1 (en) P. aeruginosa mucoid exopolysaccharide specific binding peptides
KR101363695B1 (ko) 항페리오스틴에 대한 항체, 및 페리오스틴이 관여하는 질환의 예방 또는 치료를 위해 그것을 함유하는 약제학적 조성물
CN114634575A (zh) 一种补体抑制剂的开发和应用
JP2002524099A (ja) 脈管形成の調節における内皮細胞表面受容体活性の調節
JP2003507338A (ja) レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用
CN119735674B (zh) 抗vmat2的抗体或其抗原结合片段及其组合物和应用
WO2004031240A1 (en) Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
US10131706B2 (en) Anti-factor Bb antibodies
WO2023116771A1 (zh) 一种抗masp-2抗体及其制备方法与用途
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
HK1126226A (en) Inhibitors of complement activation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100728

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101122